Skip to content

A randomized controlled trial for the Bu-Xue Yi-Mu particles in the treatment of postpartum disease

A randomized controlled trial for the Bu-Xue Yi-Mu particles in the treatment of postpartum disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028187
Enrollment
Unknown
Registered
2019-12-14
Start date
2020-02-01
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum disease (e.g., postpartum anemia, postpartum lochia, postpartum abdominal pain, Postpartum uterine instauration, postpartum pelvic floor repair, etc.)

Interventions

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Subjects' informed consent to participate voluntarily, and signed informed consent in person or by legal guardian; 2. Aged 20-40 years; 3. Maternity or cesarean delivery: 37 weeks-41 weeks + 6 days; 4. Hemoglobin is greater than 90 g/L and less than 105 g/L.

Exclusion criteria

Exclusion criteria: 1. Patients with severe medical comorbidities (heart disease, liver disease, kidney disease, etc.) have abnormal liver and kidney function; or the value of alanine aminotransferase (ALT) or or aspartate aminotransferase (AST) >2 ULN; Those: or those whose creatinine (Cr) is greater than the upper limit of normal value; 2. People with severe endocrine diseases (pre-pregnancy diabetes, hyperthyroidism, etc.); 3. those with pregnancy-induced hypertension and sepsis; 4. Reproductive tract malformations and uterine infections; 5. Placenta implantation or dangerous placenta previa; 6. Those who have failed the trial and transferred to cesarean section; 7. >=2 abdominal operations related to the uterus and >=4 deliveries; 8. those with severe coagulopathy or whose PT and or APTT values ??exceed the upper limit of normal values; or Those with platelets less than 80x10^9/L; 9. Uterine fibroids: single fibroids >=5cm; or multiple fibroids> 3, single fibroids >=2cm; 10. Those with a history of adenomyoma before pregnancy; 11. Multiple pregnancy; 12. Subjects who are taking HIV protease inhibitors; 13. Those who are allergic to the test drug; 14. Participated in other clinical researchers within three months before enrollment; 15. Researchers do not consider it appropriate to participate in this trial.

Design outcomes

Primary

MeasureTime frame
haemoglobin;lochia;Obstetrics and gynecology ultrasound;blood routine;Coagulation test;Visual Analogue Scale (VAS) Pain Score;Pelvic floor recovery test;

Countries

China

Contacts

Public ContactLing Feng

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

fltj007@163.com+86 13871402429

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026